Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants

Antiviral Research

Volumn 76, Issue 1, 2007, Pages 75-85

  Revaz, Véronique ^a   Zurbriggen, Rinaldo ^b   Moser, Christian ^b   Schiller, John T ^d   Ponci, Françoise ^a   Bobst, Martine ^a   Nardelli Haefliger, Denise ^a,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Berna Biotech AG   (Switzerland)

^c National Center of Competence in Research in Molecular Oncology   (Switzerland)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody and cell mediated immune responses; CpG ODN; HLT; Human papillomavirus type 16; Mucosal immunization; Virus like particles

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; ESCHERICHIA ENTEROTOXIN; INFLUENZA VACCINE; VIRUS ANTIGEN; WART VIRUS VACCINE;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CELLULAR IMMUNITY; CONDYLOMA; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MOUSE STRAIN; MUCOSA; NONHUMAN; PRIORITY JOURNAL; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; ENTEROTOXINS; ESCHERICHIA COLI; FEMALE; HEAT; HUMAN PAPILLOMAVIRUS 16; IMMUNITY, MUCOSAL; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; VIRION;

ESCHERICHIA COLI; HUMAN PAPILLOMAVIRUS TYPE 16; MUS; PAPILLOMAVIRIDAE;

EID: 34547467742     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.05.005     Document Type: Article

References (56)

1. Balmelli C., Roden R.B., Potts A., Schiller J.T., De Grandi P., and Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. 72 (1998) 8220-8229
2. Balmelli C., Demotz S., Acha-Orbea H., De Grandi P., and Nardelli-Haefliger D. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. J. Virol. 76 (2002) 12596-12602
3. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (2002) 244-265
4. Choi A.H., McNeal M.M., Flint J.A., Basu M., Lycke N.Y., Clements J.D., Bean J.A., Davis H.L., McCluskie M.J., VanCott J.L., and Ward R.L. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 20 (2002) 1733-1740
5. Cusi M.G., Lomagistro M.M., Valassina M., Valensin P.E., and Gluck R. Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine. Vaccine 18 (2000) 2838-2842
6. Da Silva D.M., Pastrana D.V., Schiller J.T., and Kast W.M. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 290 (2001) 350-360
7. Da Silva D.M., Schiller J.T., and Kast W.M. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 21 (2003) 3219-3227
8. De Bruijn M.L., Greenstone H.L., Vermeulen H., Melief C.J., Lowy D.R., Schiller J.T., and Kast W.M. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250 (1998) 371-376
9. Decroix N., Hocini H., Quan C.P., Bellon B., Kazatchkine M.D., and Bouvet J.P. Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens. Scand. J. Immunol. 53 (2001) 401-409
10. Dell K., Koesters R., Linnebacher M., Klein C., and Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 24 (2006) 2238-2247
11. Dupuy C., Buzoni-Gatel D., Touze A., Bout D., and Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. 73 (1999) 9063-9071
12. Freidag B.L., Melton G.B., Collins F., Klinman D.M., Cheever A., Stobie L., Suen W., and Seder R.A. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect. Immun. 68 (2000) 2948-2953
13. Freytag L.C., and Clements J.D. Mucosal adjuvants. Vaccine 23 (2005) 1804-1813
14. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., and Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166 (2001) 3451-3457
15. Gerber S., Lane C., Brown D.M., Lord E., DiLorenzo M., Clements J.D., Rybicki E., Williamson A.L., and Rose R.C. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol. 75 (2001) 4752-4760
16. Gluck R., Mischler R., Durrer P., Furer E., Lang A.B., Herzog C., and Cryz Jr. S.J. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181 (2000) 1129-1132
17. Gluck U., Gebbers J.O., and Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73 (1999) 7780-7786
18. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 20 Suppl. 1 (2001) S42-S44
19. Guidotti L.G., and Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19 (2001) 65-91
20. Harandi A.M., Sanchez J., Eriksson K., and Holmgren J. Recent developments in mucosal immunomodulatory adjuvants. Curr. Opin. Invest. Drugs 4 (2003) 156-161
21. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
22. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., Mast T.C., Robinson R., Murphy B.R., Karron R.A., Dillner J., Schiller J.T., and Lowy D.R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93 (2001) 284-292
23. Hopkins S.A., Kraehenbuhl J.P., Schodel F., Potts A., Peterson D., De Grandi P., and Nardelli-Haefliger D. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63 (1995) 3279-3286
24. Jiang W., Baker H.J., and Smith B.F. Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective. Infect. Immun. 71 (2003) 40-46
25. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 12180-12184
26. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199 (2004) 201-216
27. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
28. Lenz P., Day P.M., Pang Y.Y., Frye S.A., Jensen P.N., Lowy D.R., and Schiller J.T. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166 (2001) 5346-5355
29. Lin L., Gerth A.J., and Peng S.L. CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88. Eur. J. Immunol. 34 (2004) 1483-1487
30. Liu X.S., Abdul-Jabbar I., Qi Y.M., Frazer I.H., and Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology 252 (1998) 39-45
31. Liu X.S., Xu Y., Hardy L., Khammanivong V., Zhao W., Fernando G.J., Leggatt G.R., and Frazer I.H. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J. Immunol. 171 (2003) 4765-4772
32. Lowy D.R., and Frazer I.H. Chapter 16: prophylactic human papillomavirus vaccines. J. Natl. Cancer Inst. Monogr. (2003) 111-116
33. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., Alvarez F.B., Bautista O.M., Jansen K.U., and Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107 (2006) 18-27
34. Mariotti S., Teloni R., von Hunolstein C., Romagnoli G., Orefici G., and Nisini R. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine 20 (2002) 2229-2239
35. McCluskie M.J., and Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161 (1998) 4463-4466
36. McCluskie M.J., and Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19 (2000) 413-422
37. McCluskie M.J., Weeratna R.D., Krieg A.M., and Davis H.L. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19 (2000) 950-957
38. McDermott M.R., and Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J. Immunol. 122 (1979) 1892-1898
39. Moldoveanu Z., Love-Homan L., Huang W.Q., and Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16 (1998) 1216-1224
40. Nardelli-Haefliger D., Roden R.B., Benyacoub J., Sahli R., Kraehenbuhl J.P., Schiller J.T., Lachat P., Potts A., and De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. 65 (1997) 3328-3336
41. Nardelli-Haefliger D., Roden R.B., Balmelli C., Potts A., Schiller J.T., and De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J. Virol. 73 (1999) 9609-9613
42. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., and De Grandi P. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95 (2003) 1128-1137
43. Nardelli-Haefliger D., Lurati F., Wirthner D., Spertini F., Schiller J.T., Lowy D.R., Ponci F., and De Grandi P. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23 (2005) 3634-3641
44. Ohlschlager P., Osen W., Dell K., Faath S., Garcea R.L., Jochmus I., Muller M., Pawlita M., Schafer K., Sehr P., Staib C., Sutter G., and Gissmann L. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J. Virol. 77 (2003) 4635-4645
45. Rudolf M.P., Fausch S.C., Da Silva D.M., and Kast W.M. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166 (2001) 5917-5924
46. Schiller J.T., and Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat. Rev. Microbiol. 2 (2004) 343-347
47. Slade S.J., and Langhorne J. Production of interferon-gamma during infection of mice with Plasmodium chabaudi chabaudi. Immunobiology 179 (1989) 353-365
48. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., and Bachmann M.F. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172 (2004) 1777-1785
49. Uesaka Y., Otsuka Y., Lin Z., Yamasaki S., Yamaoka J., Kurazono H., and Takeda Y. Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb. Pathogenesis 16 (1994) 71-76
50. Valdespino-Gomez J.L., de Lourdes Garcia-Garcia M., Fernandez-de-Castro J., Henao-Restrepo A.M., Bennett J., and Sepulveda-Amor J. Measles aerosol vaccination. Curr. Top. Microbiol. Immunol. 304 (2006) 165-193
51. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Wheeler C.M., Koutsky L.A., Malm C., Lehtinen M., Skjeldestad F.E., Olsson S.E., Steinwall M., Brown D.R., Kurman R.J., Ronnett B.M., Stoler M.H., Ferenczy A., Harper D.M., Tamms G.M., Yu J., Lupinacci L., Railkar R., Taddeo F.J., Jansen K.U., Esser M.T., Sings H.L., Saah A.J., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
52. Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 5 (2002) 62-69
53. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., and Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
54. Yang R., Murillo F.M., Cui H., Blosser R., Uematsu S., Takeda K., Akira S., Viscidi R.P., and Roden R.B. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J. Virol. 78 (2004) 11152-11160
55. Yang R., Murillo F.M., Delannoy M.J., Blosser R.L., Yutzy W.H., Uematsu S., Takeda K., Akira S., Viscidi R.P., and Roden R.B. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J. Immunol. 174 (2005) 7912-7919
56. Zurbriggen R., Metcalfe I.C., Gluck R., Viret J.F., and Moser C. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev. Vaccines 2 (2003) 295-304